|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Teladoc Health, Inc. 10-K 12/31/20 126:15M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.19M
2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 43K
4: EX-10.14 Material Contract HTML 55K
5: EX-10.15 Material Contract HTML 58K
6: EX-10.16 Material Contract HTML 55K
7: EX-10.18 Material Contract HTML 46K
3: EX-10.2 Material Contract HTML 130K
8: EX-21.1 Subsidiaries List HTML 39K
9: EX-23.1 Consent of Expert or Counsel HTML 35K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 39K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 39K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 35K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 35K
20: R1 Document and Entity Information HTML 96K
21: R2 Consolidated Balance Sheets HTML 123K
22: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
23: R4 Consolidated Statements of Operations HTML 93K
24: R5 Consolidated Statements of Comprehensive Loss HTML 55K
25: R6 Consolidated Statements of Stockholders' Equity HTML 131K
26: R7 Consolidated Statements of Cash Flows HTML 159K
27: R8 Organization and Description of Business HTML 39K
28: R9 Summary of Significant Accounting Policies HTML 117K
29: R10 Revenue, Deferred Revenue, Deferred Costs and HTML 118K
Other
30: R11 Fair Value Measurements HTML 84K
31: R12 Business Acquisitions HTML 103K
32: R13 Inventories HTML 43K
33: R14 Property and Equipment, Net HTML 57K
34: R15 Intangible Assets, Net HTML 123K
35: R16 Goodwill HTML 49K
36: R17 Accrued Expenses and Other Current Liabilities HTML 63K
37: R18 Revolving Credit Facility HTML 34K
38: R19 Convertible Senior Notes HTML 185K
39: R20 Advances from Financing Companies HTML 45K
40: R21 Leases and Contractual Obligations HTML 69K
41: R22 Common Stock and Stockholders' Equity HTML 180K
42: R23 Income Taxes HTML 186K
43: R24 Sale of Assets HTML 34K
44: R25 Net Loss per Share HTML 53K
45: R26 401(k) Plan HTML 36K
46: R27 Legal Matters HTML 41K
47: R28 Subsequent Event HTML 35K
48: R29 Schedule II - Valuation and Qualifying Accounts HTML 94K
49: R30 Summary of Significant Accounting Policies HTML 188K
(Policies)
50: R31 Summary of Significant Accounting Policies HTML 38K
(Tables)
51: R32 Revenue, Deferred Revenue, Deferred Costs and HTML 112K
Other (Tables)
52: R33 Fair Value Measurements (Tables) HTML 82K
53: R34 Business Acquisitions (Tables) HTML 98K
54: R35 Inventories (Tables) HTML 44K
55: R36 Property and Equipment, Net (Tables) HTML 56K
56: R37 Intangible Assets, Net (Tables) HTML 125K
57: R38 Goodwill (Tables) HTML 49K
58: R39 Accrued Expenses and Other Current Liabilities HTML 63K
(Tables)
59: R40 Convertible Senior Notes (Tables) HTML 152K
60: R41 Advances from Financing Companies (Tables) HTML 43K
61: R42 Leases and Contractual Obligations (Tables) HTML 68K
62: R43 Common Stock and Stockholders' Equity (Tables) HTML 165K
63: R44 Income Taxes (Tables) HTML 183K
64: R45 Net Loss per Share (Tables) HTML 51K
65: R46 Summary of Significant Accounting Policies - VIE HTML 69K
(Details)
66: R47 Summary of Significant Accounting Policies - HTML 46K
Segment Information (Details)
67: R48 Summary of Significant Accounting Policies - Cash HTML 37K
and Cash Equivalents and Short-Term Investments
(Details)
68: R49 Summary of Significant Accounting Policies - PPE HTML 42K
(Details)
69: R50 Summary of Significant Accounting Policies - HTML 43K
Operating Leases (Details)
70: R51 Summary of Significant Accounting Policies - HTML 65K
Intangibles (Details)
71: R52 Summary of Significant Accounting Policies - HTML 44K
Stock-Based Compensation (Details)
72: R53 Summary of Significant Accounting Policies - HTML 34K
Foreign Currency (Details)
73: R54 Summary of Significant Accounting Policies - HTML 34K
Advertising and Marketing Expenses (Details)
74: R55 Summary of Significant Accounting Policies - HTML 42K
Concentrations (Details)
75: R56 Revenue, Deferred Revenue, Deferred Costs and HTML 39K
Other - Other Disclosures (Details)
76: R57 Revenue, Deferred Revenue, Deferred Costs and HTML 65K
Other - Disaggregation and Other (Details)
77: R58 Revenue, Deferred Revenue, Deferred Costs and HTML 41K
Other - Revenue Remaining Performance Obligation
(Details)
78: R59 Revenue, Deferred Revenue, Deferred Costs and HTML 43K
Other - Deferred Cost and Other (Details)
79: R60 Fair Value Measurements - Recurring (Details) HTML 62K
80: R61 Fair Value Measurements - Level 3 (Details) HTML 46K
81: R62 Business Acquisitions - Transactions (Details) HTML 64K
82: R63 Business Acquisitions - Assets Acquired, HTML 111K
Liabilities Assumed, Pro forma (Details)
83: R64 Inventories (Details) HTML 42K
84: R65 Property and Equipment, Net (Details) HTML 50K
85: R66 Intangible Assets, Net - Summary (Details) HTML 87K
86: R67 Intangible Assets, Net - Amortization (Details) HTML 46K
87: R68 Goodwill (Details) HTML 39K
88: R69 Accrued Expenses and Other Current Liabilities HTML 63K
(Details)
89: R70 Revolving Credit Facility (Details) HTML 46K
90: R71 Convertible Senior Notes - Due 2027 - Terms HTML 74K
(Details)
91: R72 Convertible Senior Notes - Due 2027 - Summary HTML 58K
(Details)
92: R73 Convertible Senior Notes - Livongo Notes Due 2025 HTML 68K
- Terms (Details)
93: R74 Convertible Senior Notes - Livongo Notes Due 2025 HTML 58K
- Summary (Details)
94: R75 Convertible Senior Notes - Due 2025 - Terms HTML 74K
(Details)
95: R76 Convertible Senior Notes - Due 2025 - Summary HTML 59K
(Details)
96: R77 Convertible Senior Notes - Due 2022 - Terms HTML 73K
(Details)
97: R78 Convertible Senior Notes - Due 2022 - Summary HTML 59K
(Details)
98: R79 Convertible Senior Notes - Due 2022 - Other HTML 47K
(Details)
99: R80 Convertible Senior Notes - Extinguishment HTML 37K
(Details)
100: R81 Advances from Financing Companies (Details) HTML 42K
101: R82 Leases and Contractual Obligations - Other HTML 54K
(Details)
102: R83 Leases and Contractual Obligations - Lease Cost HTML 41K
(Details)
103: R84 Leases and Contractual Obligations - Supplemental HTML 41K
Information (Details)
104: R85 Leases and Contractual Obligations - Future HTML 49K
Minimum Lease Payments (Details)
105: R86 Common Stock and Stockholders' Equity - HTML 46K
Capitalization (Details)
106: R87 Common Stock and Stockholders' Equity (Deficit) - HTML 35K
Warrants (Details)
107: R88 Common Stock and Stockholders' Equity - Stock Plan HTML 114K
and Stock Options (Details)
108: R89 Common Stock and Stockholders' Equity - Fair Value HTML 64K
Assumptions (Details)
109: R90 Common Stock and Stockholders' Equity - Restricted HTML 91K
Stock Units (Details)
110: R91 Common Stock and Stockholders' Equity - HTML 84K
Performance Stock Units (Details)
111: R92 Common Stock and Stockholders' Equity - Employee HTML 54K
Stock Purchase Plan (Details)
112: R93 Common Stock and Stockholders' Equity - HTML 47K
Compensation Costs (Details)
113: R94 Income Taxes - Components (Details) HTML 71K
114: R95 Income Taxes - Statutory Income Tax Rate HTML 57K
Reconciliation (Details)
115: R96 Income Taxes - Deferred Tax Assets, Liabilities HTML 85K
and Valuation Allowance (Details)
116: R97 Income Taxes - Carryforwards (Details) HTML 50K
117: R98 Income Taxes - Unrecognized Tax Benefits (Details) HTML 46K
118: R99 Sale of Assets (Details) HTML 36K
119: R100 Net Loss per Share (Details) HTML 59K
120: R101 401(k) Plan (Details) HTML 42K
121: R102 Subsequent Events (Details) HTML 36K
122: R103 Schedule II - Valuation and Qualifying Accounts HTML 47K
(Details)
124: XML IDEA XML File -- Filing Summary XML 226K
19: XML XBRL Instance -- tdoc-20201231x10k_htm XML 3.53M
123: EXCEL IDEA Workbook of Financial Reports XLSX 155K
15: EX-101.CAL XBRL Calculations -- tdoc-20201231_cal XML 269K
16: EX-101.DEF XBRL Definitions -- tdoc-20201231_def XML 985K
17: EX-101.LAB XBRL Labels -- tdoc-20201231_lab XML 1.96M
18: EX-101.PRE XBRL Presentations -- tdoc-20201231_pre XML 1.58M
14: EX-101.SCH XBRL Schema -- tdoc-20201231 XSD 267K
125: JSON XBRL Instance as JSON Data -- MetaLinks 522± 809K
126: ZIP XBRL Zipped Folder -- 0001558370-21-002118-xbrl Zip 546K
Exhibit 31.2
Certification
I, Mala Murthy, certify that:
1. | I have reviewed this Annual Report on Form 10-K of Teladoc Health, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 1, 2021 |
| |
| | |
| | |
/s/ MALA MURTHY | | |
| | |
Chief Financial Officer | | |
| | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/1/21 | 4, S-8 | ||
| For Period end: | 12/31/20 | 5 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/24 Teladoc Health, Inc. 10-K 12/31/23 120:12M 3/01/23 Teladoc Health, Inc. 10-K 12/31/22 121:15M Toppan Merrill Bridge/FA 2/28/22 Teladoc Health, Inc. 10-K 12/31/21 111:14M Toppan Merrill Bridge/FA 3/01/21 Teladoc Health, Inc. S-8 3/01/21 3:102K Toppan Merrill/FA |